Reply to the article “Editorial comment on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study’”, by P. A. Bunn Jr (Ann Oncol 2001; 12: 1339–1340)

Reply to “Letter to the Editor on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: an EORTC double-blind placebo-controlled phase III study’”, by V. C. G. Tjan-Heijnen, P. E. Postmus &A. Ardizzoni(Ann Oncol 2002; 13: 485–486)

Annals of Oncology ◽

10.1093/annonc/mdf139 ◽

2002 ◽

Vol 13 (3) ◽

pp. 486 ◽

Cited By ~ 1

Author(s):

P. Bunn

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study

Annals of Oncology ◽

10.1023/a:1012545507920 ◽

2001 ◽

Vol 12 (10) ◽

pp. 1359-1368 ◽

Cited By ~ 80

Author(s):

V.C.G. Tjan-Heijnen ◽

P.E. Postmus ◽

A. Ardizzoni ◽

Ch. Manegold ◽

J. Burghouts ◽

...

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Editorial comments on ‘Reduction of chemotherapy-induced febrile leucopenia by prophylactic use of ciprofloxacin and roxithromycin in small-cell lung cancer patients: An EORTC double-blind placebo-controlled phase III study’

Annals of Oncology ◽

10.1023/a:1012579018035 ◽

2001 ◽

Vol 12 (10) ◽

pp. 1339-1340 ◽

Cited By ~ 5

Author(s):

P.A. Bunn

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

Phase Iii Study ◽

Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)

Annals of Oncology ◽

10.1093/annonc/mdg073 ◽

2003 ◽

Vol 14 (2) ◽

pp. 248-257 ◽

Cited By ~ 19

Author(s):

V.C.G. Tjan-Heijnen ◽

S. Caleo ◽

P.E. Postmus ◽

A. Ardizzoni ◽

J.T.M. Burghouts ◽

...

Keyword(s):

Lung Cancer ◽

Economic Evaluation ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps10142 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS10142-TPS10142

Author(s):

Li Zhang ◽

Ting Zhou ◽

Yuxiang Ma ◽

Yunpeng Yang ◽

Wenfeng Fang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cancer Patients ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Lung Cancer Patients ◽

A Randomized, Double-blind, Placebo‑Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Case Medical Research ◽

10.31525/ct1-nct04063163 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Extensive Stage

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)

European Journal of Cancer ◽

10.1016/j.ejca.2015.04.026 ◽

2015 ◽

Vol 51 (12) ◽

pp. 1511-1528 ◽

Cited By ~ 17

Author(s):

Mary E.R. O’Brien ◽

Rabab Gaafar ◽

Baktiar Hasan ◽

Jessica Menis ◽

Tanja Cufer ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Double Blind ◽

Lung Cancer Patients ◽

Cancer Group ◽

Phase Iii Study ◽

Line Chemotherapy

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study—CALGB 30607 (Alliance)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.01.022 ◽

2017 ◽

Vol 12 (5) ◽

pp. 843-849 ◽

Cited By ~ 12

Author(s):

Maria Q. Baggstrom ◽

Mark A. Socinski ◽

Xiaofei F. Wang ◽

Lin Gu ◽

Thomas E. Stinchcombe ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Combination Chemotherapy ◽

Small Cell ◽

Phase Iii ◽

Advanced Stage ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

European Journal of Cancer ◽

10.1016/j.ejca.2014.11.015 ◽

2015 ◽

Vol 51 (3) ◽

pp. 317-326 ◽

Cited By ~ 38

Author(s):

Silvia Novello ◽

Rolf Kaiser ◽

Anders Mellemgaard ◽

Jean-Yves Douillard ◽

Sergey Orlov ◽

...

Keyword(s):

Lung Cancer ◽

Patient Reported Outcomes ◽

Small Cell ◽

Phase Iii ◽

Second Line ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Patient Reported ◽

LBA43 GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase III study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.2122 ◽

2021 ◽

Vol 32 ◽

pp. S1321

Author(s):

Y-L. Wu ◽

Q. Zhou ◽

M. Chen ◽

O. Jiang ◽

D. Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Double Blind ◽

Double Blind Placebo ◽

Unresectable Stage ◽